Announcement on Obtaining the Drug Registration Certificate for BAT2306 (Secukinumab Injection)
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(688177)"Bio-Thera Solutions, Ltd."Announcement on Obtaining the Drug Registration Certificate for BAT2306 (Secukinumab Injection)
Filed with SSE · Stock code 688177 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Bio-Thera Solutions, Ltd. on 6ix
Story so far
- Announcement on Attending the 2026 Collective Reception Day for Investors in Guangdong Jurisdiction and Interim Performance Briefing for Listed Companies in the Jurisdiction
- Announcement on Resignation of the Chief Financial Officer and Designation of the Chairman and the General Manager to Act as the Chief Financial Officer
- Announcement on Voluntary Disclosure of the Receipt of the Approval Notice for Supplementary Application for Bevacizumab Injection (POBEVCY)
Earlier from Bio-Thera Solutions
- Announcement on Attending the 2026 Collective Reception Day for Investors in Guangdong Jurisdiction and Interim Performance Briefing for Listed Companies in the Jurisdiction
- Announcement on Resignation of the Chief Financial Officer and Designation of the Chairman and the General Manager to Act as the Chief Financial Officer
- Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
- Announcement on Voluntary Disclosure of the Receipt of the Approval Notice for Supplementary Application for Bevacizumab Injection (POBEVCY)
- Announcement on Voluntary Disclosure Regarding the Progress of Receipt of Milestone Payment under the License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) Injection
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions